29 November 2024
Sofia, Bulgaria, November 29, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (the Company, SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that with the completion of the respective due dilligence procedures the first stage ot the transaction for acquisition of a pharmaceutical product portfolio consisting of CHC and prescription products. The amount of EUR 40 million due at this stage is financed with own funds and through an investment loan from a financial institution which has already been secured.
The transfer of marketing authorizations and trademarks and the organization of the trading activities on the respective market will follow.